Targeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory genes by p38 MAPK inhibitors
Rakesh Kumar Singh(National Institute of Pharmaceutical Education and Research), Ruchi Tandon(Translational Health Science and Technology Institute)
Cited by 1
Related Papers
IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies
|Nature Medicine|2021|289
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
|Nature Immunology|2024|83
Detection by super-resolution microscopy of viral proteins inside bloodborne extracellular vesicles
|Extracellular Vesicles and Circulating Nucleic Acids|2023|17